Amedisys [AMED] vs DaVita [DVA] Detailed Stock Comparison

Amedisys Inc.

NASDAQ
Loading...

DaVita Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Amedisys Inc. wins in 6 metrics, DaVita Inc. wins in 14 metrics, with 0 ties. DaVita Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amedisys Inc. DaVita Inc. Better
P/E Ratio (TTM) 39.30 16.32 DaVita Inc.
Price-to-Book Ratio 2.69 9.13 Amedisys Inc.
Debt-to-Equity Ratio 35.34 1,111.35 Amedisys Inc.
PEG Ratio -2.78 2.88 DaVita Inc.
EV/EBITDA 13.74 8.85 DaVita Inc.
Profit Margin (TTM) 3.56% 5.47% DaVita Inc.
Operating Margin (TTM) 11.70% 15.23% DaVita Inc.
EBITDA Margin (TTM) 11.70% 15.23% DaVita Inc.
Return on Equity 6.67% 64.85% DaVita Inc.
Return on Assets (TTM) 6.52% 7.32% DaVita Inc.
Free Cash Flow (TTM) $214.29M $1.31B DaVita Inc.
1-Year Return 2.68% 53.29% DaVita Inc.
Price-to-Sales Ratio (TTM) 1.38 0.75 DaVita Inc.
Enterprise Value $3.48B $24.34B DaVita Inc.
EV/Revenue Ratio 1.45 1.78 Amedisys Inc.
Gross Profit Margin (TTM) 43.96% 33.43% Amedisys Inc.
Revenue per Share (TTM) $73 $184 DaVita Inc.
Earnings per Share (Diluted) $2.57 $9.50 DaVita Inc.
Beta (Stock Volatility) 0.90 0.92 Amedisys Inc.
Short % of Float 9.90% 20.23% Amedisys Inc.

Amedisys Inc. vs DaVita Inc. Stock Performance Analysis

Loading Price Chart...

AMED
DVA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amedisys Inc.0.00%0.05%3.57%7.76%10.13%10.13%
DaVita Inc.0.52%9.20%5.01%41.51%74.72%83.17%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amedisys Inc.2.68%-14.45%-58.43%149.36%328.29%215.59%
DaVita Inc.53.29%113.75%71.55%177.81%396.45%753.76%

Performance & Financial Health Analysis: Amedisys Inc. vs DaVita Inc.

MetricAMEDDVA
Market Information
Market Cap i$3.32B$10.01B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,027,642555,313
90 Day Avg. Volume i618,767768,358
Last Close$100.99$209.75
52 Week Range$82.15 - $101.02$101.00 - $211.80
% from 52W High-0.03%-0.97%
All-Time High$325.12 (Jan 25, 2021)$211.84 (Jun 12, 2026)
% from All-Time High-68.94%-0.99%
Growth Metrics
Quarterly Revenue Growth0.05%0.10%
Quarterly Earnings Growth-0.13%-0.10%
Financial Health
Profit Margin (TTM) i0.04%0.05%
Operating Margin (TTM) i0.12%0.15%
Return on Equity (TTM) i0.07%0.65%
Debt to Equity (MRQ) i35.341,111.35
Cash & Liquidity
Book Value per Share (MRQ)$37.48$-9.50
Cash per Share (MRQ)$10.26$10.49
Operating Cash Flow (TTM) i$239.42M$1.89B
Levered Free Cash Flow (TTM) i$300.69M$1.05B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Amedisys Inc. vs DaVita Inc.

MetricAMED (Aug 31, 2025)DVA (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i39.3016.32
Forward P/E i19.769.45
PEG Ratio i-2.782.88
Price to Sales (TTM) i1.380.75
Price to Book (MRQ) i2.699.13
Market Capitalization
Market Capitalization i$3.32B$10.01B
Enterprise Value i$3.48B$24.34B
Enterprise Value Metrics
Enterprise to Revenue i1.451.78
Enterprise to EBITDA i13.748.85
Risk & Other Metrics
Beta i0.900.92
Book Value per Share (MRQ) i$37.48$-9.50

Financial Statements Comparison: Amedisys Inc. vs DaVita Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMED (2024)DVA (2025)
Revenue/Sales i2.35B13.64B
Cost of Goods Sold i1.33B9.24B
COGS % of Revenue i56.7%67.8%
Gross Profit i1.02B4.40B
Gross Margin i43.3%32.2%
Research & Development iN/AN/A
Operating Income (EBIT) i209.57M2.01B
Operating Margin i8.9%14.7%
EBITDA i292.47M2.66B
EBITDA Margin i12.5%19.5%
Pre-Tax Income i86.22M1.35B
Pre-Tax Income % of Revenue i3.7%9.9%
Income Tax i48.05M293.11M
Income Tax % of Revenue i2.0%2.1%
Net Income (Profit) i38.16M1.08B
Profit Margin i1.6%7.9%

Balance Sheet & Liquidity Metrics

MetricAMED (2024)DVA (2025)
Cash & Equivalents i303.24M676.44M
Total Current Assets i632.08M4.06B
Total Current Assets % of Revenue i26.9%29.7%
Total Current Liabilities i514.39M3.14B
Total Current Liabilities % of Revenue i21.9%23.0%
Long-Term Debt i395.42M12.34B
Long-Term Debt % of Revenue i16.8%90.4%
Total Shareholders Equity i1.18B1.16B
Retained Earnings i791.16M-328.43M
Retained Earnings % of Revenue i33.7%-2.4%
Property, Plant & Equipment i167.80M6.93B

Cash Flow Statement Comparison

MetricAMED (2024)DVA (2025)
Operating Cash Flow i144.50M1.74B
Operating Cash Flow % of Revenue i6.2%12.8%
Capital Expenditures i-6.55M-575.86M
Free Cash Flow i214.29M1.31B
FCF Margin i9.1%9.6%
Debt Repayment i0-4.79B
Common Stock Repurchase i-6.15M-1.79B

Short Interest & Institutional Ownership Analysis

MetricAMEDDVA
Shares Short i3.20M6.18M
Short Ratio i6.846.94
Short % of Float i9.90%20.23%
Shares Outstanding i32.78M68.55M
Float Shares i32.24M35.22M
% Held by Insiders i1.95%51.20%
% Held by Institutions i96.37%53.62%
% Held by Public i1.68%-4.82%

Dividend Analysis & Yield Comparison: Amedisys Inc. vs DaVita Inc.

MetricAMEDDVA
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A